Stock Research: Medical Developments International

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Medical Developments International

ASX:MVP AU000000MVP2
25
  • Value
    51
  • Growth
    40
  • Safety
    Safety
    32
  • Combined
    22
  • Sentiment
    39
  • 360° View
    360° View
    25
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Medical Developments International Limited delivers emergency medical solutions. It operates in Pain Management (Penthrox inhaled analgesic) and Respiratory (asthma/COPD products). The company serves Australia, the United States, Europe, and Asia. In the last fiscal year, the company had a market cap of $43 million, profits of $16 million, and revenue of $22 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 25 (better than 25% compared with alternatives), overall professional sentiment and financial characteristics for the stock Medical Developments International are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Medical Developments International. The only rank that is above average is the consolidated Safety Rank at 51, which means that the company has a financing structure that is safer than those of 51% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 32, which means that the share price of Medical Developments International is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 40, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 39, which means that professional investors are more pessimistic about the stock than for 61% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
ASX 300
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 36 42 17
Growth
40 43 25 39
Safety
Safety
51 21 47 45
Sentiment
39 34 30 50
360° View
360° View
25 13 14 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
62 62 62 87
Opinions Change
50 50 50 50
Pro Holdings
n/a 14 4 8
Market Pulse
47 59 48 51
Sentiment
39 34 30 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
32 36 42 17
Growth
40 43 25 39
Safety Safety
51 21 47 45
Combined
22 10 23 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
3 75 75 36
Price vs. Earnings (P/E)
60 44 66 13
Price vs. Book (P/B)
100 81 73 23
Dividend Yield
1 1 1 1
Value
32 36 42 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
76 48 95 85
Profit Growth
1 100 23 1
Capital Growth
6 1 29 78
Stock Returns
98 30 3 19
Growth
40 43 25 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
75 70 73 68
Refinancing
64 36 77 37
Liquidity
6 1 1 43
Safety Safety
51 21 47 45

Similar Stocks

Discover high‑ranked alternatives to Medical Developments International and broaden your portfolio horizons.

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Shionogi

TSE:4507
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Flight Centre Travel

ASX:FLT
Country: Australia
Industry: Hotels, Resorts & Cruise Lines
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.